Turning loss into action for Familial Hypercholesterolaemia in France Véronique Lemaître did not set out to become an advocate. She became one because she understood—through painful personal experience—what happens when familial hypercholesterolaemia (FH) is not diagnosed and treated in time. A mother first and foremost, Véronique encountered FH within her own family. Cholesterol disorders were … Continue reading Remembering Véronique Lemaître, Founder of ANHET.f
As we look back on 2025, we’re proud to share an overview of the significant milestones that shaped the year for our community. This year brought important progress across our core conditions: heterozygous familial hypercholesterolaemia (HeFH), homozygous familial hypercholesterolaemia (HoFH), elevated Lp(a), and familial chylomicronaemia syndrome (FCS). We’ve compiled a document that tracks the major regulatory updates, clinical trial results, events, and community projects from the … Continue reading Reflecting on 2025: Key Milestones for Our Community
The FH Europe Foundation is delighted to welcome FH Australia as the newest member of our international network of patient organisations dedicated to improving the lives of individuals and families affected by inherited lipid conditions HeFH, HoFH, elevated lipoprotein(a) and FCS. FH Australia brings extraordinary strength to the global movement: a lived experience–led, patient-centred organisation deeply embedded within Australia’s national research, clinical leadership, and advocacy landscape. Their commitment … Continue reading New network member - FH Australia
January marked a focused start to 2026, with FH Europe Foundation advancing patient education, research coordination, and policy engagement to turn evidence and strategy into everyday impact. Catch up on the key highlights from the January 2026 edition of the Heart Beat newsletter: FH Europe Foundation News: ESC–EAS Dyslipidaemia Guidelines: Launch of a free three-part … Continue reading FHEF January 2026 Edition Heart Beat Newsletter
